US4377526A
(en)
|
1981-05-15 |
1983-03-22 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid and its esters
|
US4526902A
(en)
|
1983-10-24 |
1985-07-02 |
Century Laboratories, Inc. |
Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
|
CA1239587A
(en)
|
1983-10-24 |
1988-07-26 |
David Rubin |
Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
|
JPS6135356A
(ja)
|
1984-07-27 |
1986-02-19 |
Nippon Oil & Fats Co Ltd |
血液脂質脂肪酸の分析方法
|
EP0347509A1
(en)
|
1988-06-21 |
1989-12-27 |
Century Laboratories Inc. |
A process of extraction and purification of polyunsaturated fatty acids from natural sources
|
US4920098A
(en)
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
ES2061519T3
(es)
|
1986-12-26 |
1994-12-16 |
Sagami Chem Res |
Procedimiento para la produccion de acido eicosapentaenoico.
|
JPS63185390A
(ja)
|
1987-01-27 |
1988-07-30 |
Suntory Ltd |
藻類によるエイコサペンタエン酸の製造方法
|
US5252333A
(en)
|
1987-04-27 |
1993-10-12 |
Scotia Holdings Plc |
Lithium salt-containing pharmaceutical compositions
|
US5198468A
(en)
|
1987-06-24 |
1993-03-30 |
Efamol Holdings Plc |
Essential fatty acid composition
|
US4843095A
(en)
|
1987-08-07 |
1989-06-27 |
Century Laboratories, Inc. |
Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
US5116871A
(en)
|
1988-09-13 |
1992-05-26 |
Efamol Holdings Plc |
Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
|
GB2223943A
(en)
|
1988-10-21 |
1990-04-25 |
Tillotts Pharma Ag |
Oral disage forms of omega-3 polyunsaturated acids
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
JP2839276B2
(ja)
|
1989-01-23 |
1998-12-16 |
日本分光工業株式会社 |
超臨界流体抽出・分離方法及び装置
|
US5457130A
(en)
|
1989-03-20 |
1995-10-10 |
Cancer Research Campaign Technology Limited |
Eicosapentaenoic acid used to treat cachexia
|
GB8906369D0
(en)
|
1989-03-20 |
1989-05-04 |
Tisdale Michael J |
Eicosapentaenoic acid
|
CA2043615C
(en)
|
1990-06-04 |
2001-08-14 |
Kazuhiko Hata |
Method of producing eicosapentaenoic acid or the ester derivative thereof
|
GB9012651D0
(en)
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
JP3103588B2
(ja)
|
1990-11-16 |
2000-10-30 |
持田製薬株式会社 |
リポプロテイン(a)低下剤
|
SE9101642D0
(sv)
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
US5215630A
(en)
|
1991-06-04 |
1993-06-01 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
|
AU2384292A
(en)
|
1991-07-30 |
1993-03-02 |
North Carolina State University |
Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
|
DE4133694C2
(de)
|
1991-10-11 |
1993-10-07 |
Fresenius Ag |
Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
|
JP3400466B2
(ja)
|
1991-10-28 |
2003-04-28 |
日本水産株式会社 |
高純度エイコサペンタエン酸またはそのエステルの製造方法
|
JPH0649479A
(ja)
|
1992-07-28 |
1994-02-22 |
Maruha Corp |
ω−3不飽和脂肪酸系化合物の安定化法
|
GB9217780D0
(en)
|
1992-08-21 |
1992-10-07 |
Efamol Holdings |
Fatty acid treatment
|
US5888541A
(en)
|
1992-08-21 |
1999-03-30 |
Scotia Holdings Plc |
Fatty acid treatment
|
GB9300125D0
(en)
|
1993-01-06 |
1993-03-03 |
Scotia Holdings Plc |
Compositions containing esters of unsaturated fatty acids
|
WO1994028891A1
(en)
|
1993-06-04 |
1994-12-22 |
Martek Biosciences Corporation |
Method of treating coronary vascular disease using docosahexaenoic acid
|
GB9318611D0
(en)
|
1993-09-08 |
1993-10-27 |
Sandoz Nutrition Ltd |
Improvements in or relating to organic compounds
|
JP3325995B2
(ja)
|
1994-02-28 |
2002-09-17 |
ミサワホーム株式会社 |
パネル接合構造
|
GB9403857D0
(en)
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
GB9404483D0
(en)
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
US5385929A
(en)
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US5760081A
(en)
|
1994-05-10 |
1998-06-02 |
The General Hospital Corporation |
Omega 3 fatty acids in the prevention of ventricular fibrillation
|
JP3368100B2
(ja)
|
1994-06-02 |
2003-01-20 |
キヤノン株式会社 |
静電荷像現像用トナー
|
AU711482B2
(en)
|
1994-06-28 |
1999-10-14 |
Scotia Holdings Plc |
Compositions for treatment of diabetic complications
|
IT1274734B
(it)
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
JP2780154B2
(ja)
|
1995-02-17 |
1998-07-30 |
株式会社ヤクルト本社 |
ヨーグルト
|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
GB9509764D0
(en)
|
1995-05-15 |
1995-07-05 |
Tillotts Pharma Ag |
Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
|
JP3552810B2
(ja)
|
1995-09-27 |
2004-08-11 |
松下電器産業株式会社 |
部品供給部の部品一括交換方法と装置
|
GB9519661D0
(en)
|
1995-09-27 |
1995-11-29 |
Scotia Holdings Plc |
Fatty acid treatment
|
US5763496A
(en)
|
1995-11-27 |
1998-06-09 |
The Research Foundation Of State University Of New York |
Prevention of atherosclerosis using NADPH oxidase inhibitors
|
AU2738497A
(en)
|
1996-04-24 |
1997-11-12 |
Brigham And Women's Hospital |
Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
|
US6077828A
(en)
|
1996-04-25 |
2000-06-20 |
Abbott Laboratories |
Method for the prevention and treatment of cachexia and anorexia
|
US6248398B1
(en)
|
1996-05-22 |
2001-06-19 |
Applied Materials, Inc. |
Coater having a controllable pressurized process chamber for semiconductor processing
|
TW425285B
(en)
|
1996-06-10 |
2001-03-11 |
Viva America Marketing Inc |
Fish oil and garlic nutritive supplement
|
US5861399A
(en)
*
|
1996-07-17 |
1999-01-19 |
Heart Care Partners |
Methods and compositions for the rapid and enduring relief of inadequate myocardial function
|
US20020055539A1
(en)
|
1996-10-02 |
2002-05-09 |
Bockow Barry I. |
Compositions and methods for treating cardiovascular conditions
|
KR100657642B1
(ko)
|
1996-10-11 |
2006-12-19 |
스카리스타 리미티드 |
에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는 오일
|
DE69622722T2
(de)
|
1996-11-20 |
2003-02-27 |
Nutricia Nv |
Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
|
US20010006644A1
(en)
*
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
EP1025842B1
(en)
|
1997-10-30 |
2004-07-21 |
Morishita Jintan Co., Ltd. |
Double-leyered capsule of unsaturated fatty acid or derivative thereof and process for producing the same
|
CA2303864A1
(en)
|
1997-11-25 |
1999-06-03 |
Warner-Lambert Company |
Inhibition of lipoprotein oxidation
|
EP1039893B1
(en)
|
1997-12-10 |
2011-02-02 |
Cyclosporine Therapeutics Limited |
Pharmaceutical compositions containing an omega-3 fatty acid oil
|
NZ500703A
(en)
|
1998-11-04 |
2001-06-29 |
F |
Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
|
US20020055529A1
(en)
|
1998-12-02 |
2002-05-09 |
Bisgaier Charles Larry |
Method for treating alzheimer's disease
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
US6193999B1
(en)
|
1999-03-01 |
2001-02-27 |
Banner Pharmacaps, Inc. |
Gum acacia substituted soft gelatin capsules
|
PT1156814E
(pt)
|
1999-03-03 |
2004-01-30 |
Eurovita A S |
Compostos farmaceuticos suplementos dieteticos e composicoes cosmeticas compreendendo um acido gordo e gengibre
|
KR100423013B1
(ko)
|
1999-03-04 |
2004-03-12 |
산토리 가부시키가이샤 |
도코사펜타엔산 함유물질의 이용
|
US7112609B2
(en)
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
CA2311974A1
(en)
|
1999-06-28 |
2000-12-28 |
Nisshin Flour Milling Co., Ltd. |
Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
|
GB9916536D0
(en)
|
1999-07-14 |
1999-09-15 |
Scarista Limited |
Nutritional or pharmaceutical compositions
|
EP1072198B1
(de)
|
1999-07-28 |
2008-05-14 |
SWISS CAPS Rechte und Lizenzen AG |
Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
|
WO2001015552A1
(en)
|
1999-08-30 |
2001-03-08 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
EP1125914A1
(en)
|
2000-02-14 |
2001-08-22 |
Nisshin Flour Milling Co., Ltd. |
Process for separating and purifying eicosapentaenoic acid or its ester
|
DK1157692T3
(da)
|
2000-05-22 |
2006-02-06 |
Pro Aparts Investimentos E Con |
Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
GB0016045D0
(en)
|
2000-06-29 |
2000-08-23 |
Laxdale Limited |
Therapeutic combinations of fatty acids
|
GB0016452D0
(en)
|
2000-07-04 |
2000-08-23 |
Kilgowan Limited |
Vitamin K and essential fatty acids
|
JP4391673B2
(ja)
|
2000-08-08 |
2009-12-24 |
花王株式会社 |
油脂組成物
|
BR0113200A
(pt)
|
2000-08-15 |
2003-09-16 |
Pfizer Prod Inc |
Combinação terapêutica
|
GB0101198D0
(en)
|
2001-01-17 |
2001-02-28 |
Scherer Technologies Inc R P |
Ingestible compositions containing an odoriferous oil
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
GB0111282D0
(en)
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
SK14502003A3
(en)
|
2001-05-30 |
2004-10-05 |
Laxdale Ltd |
Coenzyme Q and eicosapentaenoic acid
|
US20120214771A1
(en)
|
2001-07-27 |
2012-08-23 |
Fontini Sampalis |
Compositions for treatment of cardiometabolic disorders
|
ITMI20012384A1
(it)
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
US20030144219A1
(en)
|
2001-11-15 |
2003-07-31 |
Phinney Stephen Dodge |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
ITMI20020269A1
(it)
|
2002-02-12 |
2003-08-12 |
Victorix Assets Ltd |
Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
|
JP2003306690A
(ja)
|
2002-02-18 |
2003-10-31 |
Nooburu:Kk |
多価不飽和脂肪酸含有油脂組成物
|
US20030166614A1
(en)
*
|
2002-03-01 |
2003-09-04 |
Harrison Stanley F. |
Method for reducing cholesterol and triglycerides
|
EP1549299B1
(en)
|
2002-06-05 |
2014-08-20 |
IVAX Pharmaceuticals s.r.o. |
Reduction of gelatin cross-linking
|
US7157235B2
(en)
|
2002-06-17 |
2007-01-02 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
US20040001874A1
(en)
|
2002-06-24 |
2004-01-01 |
Vital Living, Inc. |
Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
|
JP2005532394A
(ja)
|
2002-07-02 |
2005-10-27 |
ガリレオ ファーマシューティカルズ, インコーポレイティド |
雌性被験体における炎症性症状および/またはバイオマーカーの低減のための組成物および方法
|
US20060211761A1
(en)
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
EP1547588B1
(en)
|
2002-08-20 |
2013-12-11 |
Kowa Company, Ltd. |
Soft capsule preparation
|
KR100539027B1
(ko)
|
2002-10-18 |
2005-12-26 |
현대모비스 주식회사 |
차량의 조향각 검출 장치
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US8017651B2
(en)
|
2002-11-22 |
2011-09-13 |
Bionexus, Ltd. |
Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
|
AU2003284617A1
(en)
|
2002-11-22 |
2004-06-18 |
Nippon Suisan Kaisha, Ltd. |
Composition containing organic substance having double bond with improved oxidation stability
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
GB0301701D0
(en)
|
2003-01-24 |
2003-02-26 |
Ensay Ltd |
Psoriasis and Eicosapentaenoic acid
|
JP5362944B2
(ja)
|
2003-02-07 |
2013-12-11 |
持田製薬株式会社 |
くも膜下出血の予後改善剤
|
CA2516333C
(en)
|
2003-02-21 |
2011-08-23 |
Mochida Pharmaceutical Co., Ltd. |
Drug for reducing side effects in ribavirin / interferon combination therapy
|
JP2006519244A
(ja)
|
2003-03-05 |
2006-08-24 |
ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病患者の治療におけるω−3−脂肪酸の使用
|
EP1605781A1
(en)
|
2003-03-18 |
2005-12-21 |
Novartis AG |
Compositions comprising fatty acids and amino acids
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US6846942B2
(en)
|
2003-05-20 |
2005-01-25 |
David Rubin |
Method for preparing pure EPA and pure DHA
|
US7205329B2
(en)
|
2003-05-30 |
2007-04-17 |
Microbia, Inc. |
Modulators of CRTH2 activity
|
WO2004112777A1
(ja)
|
2003-06-20 |
2004-12-29 |
Mochida Pharmaceutical Co., Ltd. |
下肢静脈瘤予防・治療用組成物
|
US20050042214A1
(en)
|
2003-07-15 |
2005-02-24 |
Gershwin M. Eric |
Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
|
EP1558220B1
(en)
|
2003-07-24 |
2010-02-10 |
Wockhardt Limited |
Oral compositions for treatment of diabetes
|
EP1685239B1
(en)
|
2003-11-12 |
2014-05-21 |
E.I. Du Pont De Nemours And Company |
Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
|
ITMI20032247A1
(it)
|
2003-11-19 |
2005-05-20 |
Tiberio Bruzzese |
Interazione di derivati polari di composti insaturi con substrati inorganici
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
GB2409644B
(en)
|
2003-12-31 |
2005-12-21 |
Igennus Ltd |
Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1591114A1
(en)
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
US7923043B2
(en)
*
|
2004-03-30 |
2011-04-12 |
Theta Biomedical Consulting & Development Co., Inc. |
Method for protecting humans against superficial vasodilator flush syndrome
|
US20050244367A1
(en)
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
WO2005114190A2
(en)
|
2004-05-19 |
2005-12-01 |
Ppd Biomarker Discovery Sciences, Llc |
Methods of identifying biomarkers
|
TW200613009A
(en)
|
2004-06-11 |
2006-05-01 |
Ono Pharmaceutical Co |
Capsule having chewing stability
|
GB0413730D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
GB0413729D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
ITRM20040395A1
(it)
|
2004-08-03 |
2004-11-03 |
Sigma Tau Ind Farmaceuti |
Composizione comprendente statine e acidi grassi omega 3.
|
WO2006017627A2
(en)
|
2004-08-06 |
2006-02-16 |
Barry Sears |
Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
|
JP2008509154A
(ja)
|
2004-08-06 |
2008-03-27 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なスタチン薬剤組成物および関連治療方法
|
CA2577345C
(en)
|
2004-08-18 |
2013-02-19 |
Hiroki Ueshima |
Jelly composition
|
EP2404605B1
(en)
|
2004-08-25 |
2015-04-22 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
CA2581775A1
(en)
|
2004-09-27 |
2006-04-06 |
Sigmoid Biotechnologies Limited |
Dihydropyrimidine microcapsule - formulations
|
WO2006085144A2
(en)
|
2004-10-15 |
2006-08-17 |
Photonz Corporation Limited |
Compositions containing high omega-3 and low saturated fatty acid levels
|
FR2878747B1
(fr)
|
2004-12-03 |
2007-03-30 |
Pierre Fabre Medicament Sa |
Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
|
MX2007006707A
(es)
|
2004-12-06 |
2008-01-16 |
Reliant Pharmaceuticals Inc |
Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
|
CN101098690A
(zh)
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
US20070191467A1
(en)
|
2004-12-06 |
2007-08-16 |
Reliant Pharmaceutical, Inc. |
Statin and omega-3 fatty acids for lipid therapy
|
US20060135610A1
(en)
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
GB2421909A
(en)
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
US20080200707A1
(en)
|
2005-01-04 |
2008-08-21 |
Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. |
Lipotoxicity Relieving Agent
|
WO2006073147A1
(ja)
|
2005-01-04 |
2006-07-13 |
Mochida Pharmaceutical Co., Ltd. |
脂肪毒性の改善剤
|
US20060172012A1
(en)
|
2005-01-28 |
2006-08-03 |
Finley John W |
Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
|
US20060189682A1
(en)
|
2005-02-02 |
2006-08-24 |
Payne Joseph E |
Water soluble prodrugs of COX-2 inhibitors
|
CA2598273A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
US20100254951A1
(en)
|
2005-02-22 |
2010-10-07 |
Mochida Pharmaceutical Co., Ltd. |
Nerve Regeneration Promoting Agent
|
CN101208083A
(zh)
|
2005-03-08 |
2008-06-25 |
瑞莱恩特医药品有限公司 |
利用他汀和Omega-3脂肪酸治疗及其组合产品
|
EP1790339B1
(en)
|
2005-07-08 |
2014-06-04 |
Mochida Pharmaceutical Co., Ltd. |
Composition for prevention of occurrence of cardiovascular event
|
JP5134916B2
(ja)
|
2005-07-08 |
2013-01-30 |
持田製薬株式会社 |
心血管イベント発症予防用組成物
|
WO2007011886A2
(en)
|
2005-07-18 |
2007-01-25 |
Reliant Pharmaceuticals, Inc. |
Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof
|
US7628027B2
(en)
|
2005-07-19 |
2009-12-08 |
Hussmann Corporation |
Refrigeration system with mechanical subcooling
|
EA200800451A1
(ru)
|
2005-07-28 |
2008-08-29 |
Релайэнт Фармасьютикалз, Инк. |
Лечение дигидропиридиновыми блокаторами кальциевых каналов и жирными кислотами омега-3 и их комбинированным продуктом
|
ITMI20051560A1
(it)
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
EP1948168A4
(en)
|
2005-10-28 |
2010-10-06 |
Numerate Inc |
COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND / OR HMG-COA REDUCTASE
|
US20070105793A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Curt Hendrix |
Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
|
US20070104779A1
(en)
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
BRPI0618455A2
(pt)
*
|
2005-11-11 |
2011-08-30 |
Mochida Pharm Co Ltd |
composição de geléia
|
WO2007058523A1
(en)
|
2005-11-17 |
2007-05-24 |
N.V. Nutricia |
Composition with docosapentaenoic acid
|
RU2395280C2
(ru)
|
2005-11-21 |
2010-07-27 |
Тева Фармасьютикл Индастриес Лтд. |
Фармацевтическая лекарственная форма аторвастатина
|
JP2009520824A
(ja)
*
|
2005-12-20 |
2009-05-28 |
セネストラ エルエルシー |
オメガ3脂肪酸製剤
|
ATE509624T1
(de)
|
2005-12-23 |
2011-06-15 |
Nutricia Nv |
Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
|
WO2007081773A2
(en)
|
2006-01-05 |
2007-07-19 |
Reliant Pharmaceuticals, Inc |
Treatment of fatty liver
|
EP1905424A3
(en)
|
2006-02-02 |
2008-04-30 |
Ranbaxy Laboratories Limited |
Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
|
WO2007091338A1
(ja)
|
2006-02-07 |
2007-08-16 |
Mochida Pharmaceutical Co., Ltd. |
脳卒中再発予防用組成物
|
JP5069448B2
(ja)
|
2006-02-07 |
2012-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
BRPI0707794A2
(pt)
|
2006-02-14 |
2011-05-10 |
Intercept Pharmaceuticals Inc |
compostos derivados de Ácido biliar, formulaÇÕes e composiÇÕes farmacÊuticas, bem como uso de ditos compostos
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
WO2007128801A1
(en)
*
|
2006-05-08 |
2007-11-15 |
Novartis Ag |
Combination of organic compounds
|
EP2777701A1
(en)
*
|
2006-05-31 |
2014-09-17 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid
|
CA2656311C
(en)
|
2006-07-05 |
2016-06-21 |
Photonz Corporation Limited |
Ultra pure epa and polar lipids produced in largely heterotrophic culture
|
US20090304784A1
(en)
|
2006-07-28 |
2009-12-10 |
V. Mane Fils |
Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
|
US20080085911A1
(en)
|
2006-10-10 |
2008-04-10 |
Reliant Pharmaceuticals, Inc. |
Statin and omega-3 fatty acids for reduction of apo-b levels
|
CN101553221A
(zh)
|
2006-10-10 |
2009-10-07 |
瑞莱恩特医药品有限公司 |
用于降低APO-B水平的抑制素和ω-3脂肪酸
|
JP2010506920A
(ja)
|
2006-10-18 |
2010-03-04 |
リライアント・ファーマシューティカルズ・インコーポレイテッド |
Lp−pla2濃度を減少させるためのオメガ−3脂肪酸
|
WO2008047340A1
(en)
*
|
2006-10-19 |
2008-04-24 |
Mor Research Applications Ltd. |
Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
US20080306154A1
(en)
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
WO2008088030A1
(ja)
|
2007-01-17 |
2008-07-24 |
Mochida Pharmaceutical Co., Ltd. |
血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
|
WO2008091338A1
(en)
*
|
2007-01-23 |
2008-07-31 |
Reddy Us Therapeutics, Inc. |
Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
|
US20080185198A1
(en)
|
2007-02-02 |
2008-08-07 |
Steven Mark Jones |
Next generation hybrid III parallel/series hybrid system
|
ES2561482T3
(es)
|
2007-02-15 |
2016-02-26 |
Centre De Recherche Sur Les Biotechnologies Marine |
Monoglicéridos de ácido graso poliinsaturado, derivados, y sus usos
|
WO2008106787A1
(en)
|
2007-03-06 |
2008-09-12 |
Bioriginal Food & Science Corporation |
Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
|
WO2008115529A1
(en)
|
2007-03-20 |
2008-09-25 |
Reliant Pharmaceuticals, Inc. |
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
WO2008145170A1
(de)
|
2007-05-31 |
2008-12-04 |
Siemens Aktiengesellschaft |
Verfahren zum konfigurieren einer automatisierungsanlage
|
US20080299187A1
(en)
|
2007-06-01 |
2008-12-04 |
Joar Opheim |
Substances for Reducing Occurence of Major Cardiac Events in Humans
|
AU2008272135B2
(en)
|
2007-06-29 |
2013-10-31 |
Takeda Pharmaceutical Company Limited |
Seamless capsule
|
US8969400B2
(en)
|
2007-10-01 |
2015-03-03 |
Duke University |
Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
|
JP5421126B2
(ja)
|
2008-01-10 |
2014-02-19 |
武田薬品工業株式会社 |
カプセル製剤
|
US20090182049A1
(en)
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
EP2291499B1
(en)
|
2008-05-15 |
2020-02-12 |
Basf As |
Krill oil process
|
CA2724983A1
(en)
|
2008-05-20 |
2009-11-26 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing cardiovascular event in high-risk patient
|
WO2009151125A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
肝障害の診断及び治療
|
WO2009151116A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
JPWO2009154230A1
(ja)
|
2008-06-17 |
2011-12-01 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
EP2308493A4
(en)
|
2008-07-07 |
2013-05-01 |
Mochida Pharm Co Ltd |
ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
|
US20110236476A1
(en)
*
|
2008-09-02 |
2011-09-29 |
Amarin Corporation Plc. |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
CA2738985A1
(en)
|
2008-09-30 |
2010-04-08 |
Mochida Pharmaceutical Co., Ltd. |
Therapeutic agent for hepatitis c
|
US20100130608A1
(en)
|
2008-10-01 |
2010-05-27 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
KR20140007973A
(ko)
|
2009-02-10 |
2014-01-20 |
아마린 파마, 인크. |
고중성지방혈증 치료 방법
|
US8241672B2
(en)
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
NZ627238A
(en)
|
2009-04-29 |
2016-02-26 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition comprising ethyl eicosapentaenoate
|
NZ624963A
(en)
|
2009-04-29 |
2016-07-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
JP5313343B2
(ja)
|
2009-05-22 |
2013-10-09 |
持田製薬株式会社 |
ω3脂肪酸の自己乳化組成物
|
MY172372A
(en)
|
2009-06-15 |
2019-11-21 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for lowering triglycerides
|
RU2402326C1
(ru)
|
2009-06-22 |
2010-10-27 |
Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) |
Способ коррекции инсулинорезистентности при метаболическом синдроме
|
US8557275B2
(en)
|
2009-07-23 |
2013-10-15 |
U.S. Nutraceuticals, LLC |
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
|
WO2011038122A1
(en)
|
2009-09-23 |
2011-03-31 |
Amarin Corporation Plc |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
EP2488022B1
(en)
|
2009-10-16 |
2018-01-10 |
Mochida Pharmaceutical Co., Ltd. |
Compositions
|
WO2011046204A1
(ja)
|
2009-10-16 |
2011-04-21 |
持田製薬株式会社 |
非アルコール性脂肪肝炎関連マーカー
|
US20110178105A1
(en)
|
2010-01-15 |
2011-07-21 |
E.I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
KR20130026428A
(ko)
|
2010-03-04 |
2013-03-13 |
아마린 파마, 인크. |
심혈관 질환을 치료 및/또는 예방하기 위한 조성물 및 방법
|
US8846321B2
(en)
|
2010-03-12 |
2014-09-30 |
President And Fellows Of Harvard College |
Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
|
US8663704B2
(en)
|
2010-04-30 |
2014-03-04 |
U.S. Nutraceuticals, LLC |
Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
|
AU2011249630B2
(en)
|
2010-05-05 |
2014-01-23 |
St. Giles Foods Limited |
Edible compositions and methods of manufacturing edible compositions
|
ES2710540T5
(es)
|
2010-06-30 |
2022-08-26 |
Mochida Pharm Co Ltd |
Preparación de compuesto de ácido graso omega-3
|
WO2012054555A2
(en)
|
2010-10-20 |
2012-04-26 |
Glycomark, Inc. |
Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
|
NZ744990A
(en)
|
2010-11-29 |
2019-10-25 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
KR101310710B1
(ko)
|
2011-03-23 |
2013-09-27 |
한미약품 주식회사 |
오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
|
US20120264824A1
(en)
|
2011-04-15 |
2012-10-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
DK3357497T3
(en)
|
2011-04-27 |
2020-11-23 |
Ionis Pharmaceuticals Inc |
Modulation af apolipoprotein ciii (apociii) ekspression
|
WO2013040507A1
(en)
|
2011-09-15 |
2013-03-21 |
Omthera Pharmaceuticals, Inc. |
Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US20140323709A1
(en)
|
2011-12-12 |
2014-10-30 |
National Cerebral And Cardiovascular Center |
Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
WO2013148136A1
(en)
|
2012-03-30 |
2013-10-03 |
Sancilio & Company, Inc. |
Omega-3 fatty acid ester compositions
|
AR095182A1
(es)
|
2012-05-07 |
2015-09-30 |
Omthera Pharmaceuticals Inc |
Composiciones de estatinas y ácidos grasos omega-3
|
JP6254939B2
(ja)
|
2012-05-15 |
2017-12-27 |
持田製薬株式会社 |
高血中高感度c反応性蛋白質患者の心血管疾患一次予防剤
|
US20130324607A1
(en)
|
2012-06-05 |
2013-12-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypercholesterolemia
|
US20140080850A1
(en)
|
2012-06-05 |
2014-03-20 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
|
WO2013192109A1
(en)
|
2012-06-17 |
2013-12-27 |
Matinas Biopharma, Inc. |
Omega-3 pentaenoic acid compositions and methods of use
|
US20140004183A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating cardiovascular disease in statin-tolerant subjects
|
US20150157593A1
(en)
|
2012-06-29 |
2015-06-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing ldl-p
|
EP2866801A4
(en)
|
2012-06-29 |
2016-02-10 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT
|
US20140005265A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating hypertriglyceridemia
|
US20140005264A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating pediatric metabolic syndrome
|
CA2886178C
(en)
|
2012-09-28 |
2020-12-01 |
Mochida Pharmaceutical Co., Ltd. |
Composition for reducing new-onset diabetes
|
US9486433B2
(en)
|
2012-10-12 |
2016-11-08 |
Mochida Pharmaceuticals Co. Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
EP2719382A1
(en)
|
2012-10-12 |
2014-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US20140213648A1
(en)
|
2012-12-31 |
2014-07-31 |
Amarin Pharmaceuticals Ireland Limited |
Methods of increasing epa blood levels
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US20140221676A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US20140221358A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
|
US20140221452A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US20140249225A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20140249200A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
|
US20140249220A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
|
US20140249214A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of warfarin and ethyl eicosapentaenoate
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140275252A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating traumatic brain injury
|
US20140271907A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US20140357717A1
(en)
|
2013-06-04 |
2014-12-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
ES2817527T3
(es)
|
2013-07-18 |
2021-04-07 |
Mochida Pharm Co Ltd |
Composición autoemulsionante de ácidos grasos omega-3
|
JPWO2015008848A1
(ja)
|
2013-07-18 |
2017-03-02 |
持田製薬株式会社 |
ω3脂肪酸の自己乳化組成物
|
WO2015021141A1
(en)
|
2013-08-06 |
2015-02-12 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
|
US20150051282A1
(en)
|
2013-08-14 |
2015-02-19 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US20150073050A1
(en)
|
2013-09-09 |
2015-03-12 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
|
EP3054940B1
(en)
|
2013-10-07 |
2020-09-23 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
WO2015066512A1
(en)
|
2013-10-31 |
2015-05-07 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
MX369921B
(es)
|
2014-04-11 |
2019-11-26 |
Cymabay Therapeutics Inc |
Tratamiento de la hgna y ehna.
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
WO2016019223A1
(en)
|
2014-08-01 |
2016-02-04 |
Western Michigan University Research Foundation |
Self-supported electronic devices
|
KR102488648B1
(ko)
|
2015-01-21 |
2023-01-12 |
모치다 세이야쿠 가부시키가이샤 |
ω3 지방산의 자기 유화 조성물
|
EP3248599B1
(en)
|
2015-01-21 |
2022-07-06 |
Mochida Pharmaceutical Co., Ltd. |
Omega-3 fatty acid self-emulsifying composition
|
US20180028480A1
(en)
|
2015-03-02 |
2018-02-01 |
Richard Preston Mason |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20170151202A1
(en)
|
2015-09-09 |
2017-06-01 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|